Our latest research, company updates and industry insight
The ClearSky Medical Diagnostics team is attending the International Parkinson and Movement Disorder Society (MDS) Congress in Madrid.
ClearSky’s co-founder Professor Stephen Smith discusses disruptive healthcare technologies in neurodegenerative diseases in the latest SCOR Innovation Podcast.
ClearSky Medical Diagnostics has attended and exhibited at the 35th Global Conference of Alzheimer’s Disease International in June 2022.
ClearSky Medical Diagnostics has developed an intelligent medical device that can objectively diagnose mild cognitive impairment (MCI), a condition often suggested as an early stage of dementia.
ClearSky Medical Diagnostics is supporting a new initiative to better understand the development of children’s brains during their early stages of life.
ClearSky Medical Diagnostics and Shanghai Accurature Diagnostics Co Ltd have entered into a strategic cooperation agreement related to PD-Monitor.
PD-Monitor could differentiate Parkinson’s from essential tremor without bradykinesia with high accuracy, sensitivity and specificity – according to a study.
Professor Smith highlighted the work of ClearSky in diagnosing and monitoring Parkinson’s at a UK–China university consortium in November.
ClearSky’s PD-Monitor has been used in a nationwide study to investigate whether statins are effective in slowing the progress of Parkinson’s.
ClearSky Medical Diagnostics is recognised as an ‘up and coming’ company tackling neurodegenerative disease through technology.
ClearSky has launched a new study in China to establish introducing bradykinesia as a feature being measured by LID-Monitor.
ClearSky’s Professor Stephen Smith hosted a stand at an innovation exchange event in Leeds in January – part of a prestigious international innovation programme that the city of Leeds was chosen to host with Massachusetts Institute of Technology (MIT).